<DOC>
	<DOCNO>NCT02497599</DOCNO>
	<brief_summary>Intraoperative tumor localization resection enhance use intraoperative fluorescence image radiodetection . Girentuximab specifically recognize carbonic anhydrase IX express &gt; 95 % renal cell carcinoma ( RCC ) . Therefore Indium-111-DOTA-girentuximab-IRDye800CW perfect dual-labeled antibody dual-modality image-guided surgery RCC . The aim study assess feasibility safety intraoperative dual-modality image Indium-111-DOTA-girentuximab-IRDye800CW renal cell carcinoma patient .</brief_summary>
	<brief_title>Intraoperative Dual-modality Imaging Renal Cell Carcinoma</brief_title>
	<detailed_description>In oncologic surgery complete tumor resection important treatment outcome patient survival . Intraoperative tumor localization resection enhance use intraoperative imaging technique ( e.g . target radioguided fluorescence guide surgery ) . A powerful synergy achieve combine radiotracers ( e.g . Indium-111 ) optical tracer ( e.g . IRDye 800CW ) conjugate antibody tumor-associated antigen . Girentuximab specifically recognize carbonic anhydrase IX express &gt; 95 % renal cell carcinoma ( RCC ) . Therefore Indium-111-DOTA-girentuximab-IRDye800CW perfect dual-labeled antibody dual-modality image-guided surgery RCC . The concept show preclinical study mice investigator translate clinic . Eligible patient renal cell carcinoma schedule ( partial ) nephrectomy receive dual-labeled girentuximab 7 day surgery . At day 4 5 SPECT/CT abdomen obtain . Surgery day 7 extend use near-infrared fluorescence camera gamma probe . The aim study assess feasibility safety intraoperative dual-modality image Indium-111-DOTA-girentuximab-IRDye800CW renal cell carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Clinical diagnosis clear cell renal cell carcinoma plan surgery , ( partial ) nephrectomy Performance status : Karnofsky 70 % Being fit surgery Minimum age 18 year Signed informed consent A know subtype clear cell RCC Any medical condition present opinion investigator affect patient ' clinical status . Administration radioisotope within 10 physical half live prior study enrollment Pregnancy lactation Evidence QT prolongation screen ECG Had within 6 month prior enrollment : Myocardial infarction , uncontrolled heart failure , unstable angina pectoris .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>